BAI Li,LIU Guangyun,ZHANG Xiaoping,et al.Effect of Total Flavonoids in Flower of Paeonia suffruticosa on Uric Acid in Rats with Hyperuricemia[J].Chinese Journal of Experimental Traditional Medical Formulae,2022,28(18):38-45.
BAI Li,LIU Guangyun,ZHANG Xiaoping,et al.Effect of Total Flavonoids in Flower of Paeonia suffruticosa on Uric Acid in Rats with Hyperuricemia[J].Chinese Journal of Experimental Traditional Medical Formulae,2022,28(18):38-45. DOI: 10.13422/j.cnki.syfjx.20220905.
Effect of Total Flavonoids in Flower of Paeonia suffruticosa on Uric Acid in Rats with Hyperuricemia
To explore the pharmacodynamic effects of total flavonoids of
Paeonia suffruticosa
flower (TFPFs) on rats with hyperuricemia and provide scientific data support for the research and development of therapeutic drugs for hyperuricemia.
Method
2
The hyperuricemia model was induced by adenine combined with ethambutol in rats. The rats were randomly divided into a blank control group, a model group, two positive control groups (allopurinol at 42 mg·kg
-1
and Tongfengshu tablets at 600 mg·kg
-1
), and high-, medium-, and low-dose TFPFs groups (260, 130, and 65 mg·kg
-1
). The general conditions of rats were observed and recorded, and the body weight was recorded once every 5 days. The 24-hour urine volume, water intake, uric acid (UA), and urinary protein of rats were determined after the last administration. The kidney index was calculated. The pathological changes in thymus and spleen tissues of rats were observed by hematoxylin-eosin (HE) staining. The serum activities of UA, creatinine (Cr), blood urea nitrogen (BUN), malondialdehyde (MDA), superoxide dismutase (SOD), and total antioxidant capacity (T-AOC) of rats were determined. The xanthine oxidase (XOD) and adenosine deaminase (ADA) activities in the liver were detected. The content of uric acid transporter 1 (URAT1), organic anion transporter 1 (OAT1), and glucose transporter 9 (GLUT9) in the kidney was detected by enzyme-linked immunosorbent assay (ELISA).
Result
2
Compared with the results in the model group, TFPFs could improve the mental state of rats, increase the body weight(
P
<
0.01), promote UA excretion(
P
<
0.01), reduce the content of urinary protein(
P
<
0.05), relieve renal glomerular atrophy, renal tubular epithelial cell status, and urate crystal deposition in renal tubules, dwindle 24-hour urine volume, water intake, kidney index(
P
<
0.05), serum levels of UA, Cr, BUN, and MDA(
P
<
0.05,
P
<
0.01), inhibit the activities of XOD(
P
<
0.05) and ADA(
P
<
0.05,
P
<
0.01)in the liver, diminish the expression of GLUT9 in the renal homogenate(
P
<
0.05), and increase serum SOD and T-AOC activities as well as OAT1 expression(
P
<
0.01) in the kidney. The pathological changes of thymus and spleen were improved.
Conclusion
2
TFPFs possess a protective effect on the kidney of rats with hyperuricemia, which is achieved by promoting uric acid excretion, inhibiting oxidation and the activity of key enzymes in uric acid synthesis, and regulating the expression of uric acid transporters.
LUO S F,CHIN C Y,HO L J,et al.Monosodium urate crystals induced ICAM-1 expression and cell-cell adhesion in renal mesangial cells: Implications for the pathogenesis of gouty nephropathy[J].J Microbiol Immunol Infect,2020,53(1):23-32.
LIU X,LV Q,REN H,et al.The altered gut microbiota of high-purine-induced hyperuricemia rats and its correlation with hyperuricemia[J].Peer J,2020,8:e8664.
NIU Y,ZHOU Y,LIN H,et al.Inhibition of 3,5,2',4'-tetrahydroxychalcone on production of uric acid in hypoxanthine-induced hyperuricemic mice[J].Biol Pharm Bull,2018,41(1):99-105.
TAN P K,FARRAR J E,GAUCHER E A,et al.Coevolution of URAT1 and uricase during primate evolution: Implications for serum urate homeostasis and gout[J].Mol Biol Evol,2016,33(9):2193-2200.
NIGAM S K.The SLC22 transporter family: A paradigm for the impact of drug transporters on metabolic pathways, signaling, and disease[J].Annu Rev Pharmacol Toxicol,2018,58:663-687.
LI X,YAN Z,TIAN J,et al.Urate Transporter URAT1 in Hyperuricemia: New Insights from Hyperuricemic models[J].Ann Clin Lab Sci,2019,49(6):756-762.
CRAVEDI P,REMUZZI G.Pathophysiology of proteinuria and its value as an outcome measure in chronic kidney disease[J].Br J Clin Pharmacol,2013,76(4):516-523.